LACE+指数预测脑肿瘤患者30天再入院
该研究在单一多医院学术医疗中心分析352例幕上脑肿瘤开颅手术患者,评估LACE+指数预测30天再入院、再手术和急诊就诊的能力。结果显示LACE+评分每增加1单位与30天再入院风险轻度升高相关,但模型区分度差(C统计量=0.58),不支持其作为该人群的预测模型。
要点
- LACE+评分每增加1单位,30天再入院风险约增加2%,但预测特异性差(C统计量=0.58)。
- LACE+评分每增加1单位与居家出院几率降低2%相关(C统计量=0.70)。
- LACE+指数不能预测30天再手术或30天急诊就诊。
核心结论
- LACE+指数目前尚不适合作为脑肿瘤人群30天再入院的预测模型,尽管其与再入院风险存在轻度统计学关联,但模型区分度差。
研究设计与样本
- 单中心多医院学术医疗中心分析幕上脑肿瘤开颅手术患者,纳入术后30天存活者352例,采用简单逻辑回归评估LACE+指数及单变量对30天再入院、再手术和急诊就诊的预测能力,以C统计量评价区分度。
主要发现
- LACE+评分每增加1单位,30天再入院风险约为原来的1.02倍(P=0.031,CI=1.00-1.03)。
- LACE+评分每增加1单位,居家出院几率降低2%(P<0.001,CI=0.97-0.99,C统计量=0.70)。
- LACE+指数不能预测30天再手术(P=0.945)或30天急诊就诊(P=0.218)。
- LACE+指数预测30天再入院的C统计量为0.58,提示区分度差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The LACE+ index (Length of stay, Acuity of admission, Charlson Comorbidity Index score, and Emergency department [ED] visits in the past 6 months) is a tool used to predict 30-day readmissions. We sought to examine this predictive tool in patients undergoing brain tumor surgery. METHODS: Admissions and readmissions for patients undergoing craniotomy for supratentorial neoplasm at a single multihospital academic medical center were analyzed. All brain tumor cases for which the patient was alive at 30 days after surgery were included (n = 352). Simple logistic regression analyses were used to assess the ability of the LACE+ index and subsequent single variables to accurately predict the outcome measures of 30-day readmission, reoperation, and ED visit. Analysis of the model's or variable's discrimination was determined by the receiver operating characteristic curve as represented by the C-statistic. RESULTS: The sample included admissions for craniotomy for supratentorial neoplasm (n = 352). Assessment of the LACE+ index demonstrates a 1.02× increased odds of 30-day readmission for every 1-unit increase in LACE+ score (P = 0.031, CI = 1.00-1.03). Despite this, analysis of the receiver operating characteristic curve indicates that LACE+ index has poor specificity in predicting 30-day readmission (C-statistic = 0.58). A 1-unit increase in LACE+ score also predicts a 0.98× reduction in odds of home discharge (P < 0.001, CI = 0.97-0.99, C-statistic = 0.70). But LACE+ index does not predict 30-day reoperation (P = 0.945) or 30-day ED visits (P = 0.218). CONCLUSIONS: The results of this study demonstrate that the LACE+ index is not yet suitable as a prediction model for 30-day readmission in a brain tumor population.
引用
- Caplan IF, Sullivan PZ, Kung D, et al. LACE+ Index as Predictor of 30-Day Readmission in Brain Tumor Population. World Neurosurg. 2019. PMID: 30926557. doi:10.1016/j.wneu.2019.03.169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。